ROME, June 21, 2010 (GLOBE NEWSWIRE) -- Immunomedics Inc. (Nasdaq:IMMU) today announced that clinical trial results from the Phase IIb EMBLEM™ study of epratuzumab, a monoclonal antibody targeting CD22, in patients with moderate-severe systemic lupus erythematosus were presented at the 2010 annual Congress of the European League Against Rheumatism (EULAR) in Rome, Italy.